| Abstrakt: |
A recent study conducted by researchers at the University of Michigan explores the use of IV fosfomycin for the treatment of multi-drug resistant gram-negative bacterial infections. The study aimed to determine the optimal dosage of IV fosfomycin for patients with varying degrees of kidney function. The researchers found that a dosage of 15 g/day, adjusted according to kidney function, provided high target attainment and cumulative fractions of response when treating Escherichia coli infections. However, higher dosages may be necessary for Pseudomonas aeruginosa, although safety data is limited. This research suggests that lower dosages of IV fosfomycin may improve tolerability and efficacy in treating gram-negative bacterial infections. [Extracted from the article] |
